1
Gastrointestinal Diseases Market, by Drug
Category, and Geography – Global
Opportunity Analysis and Industry
Forecast, 2...
2
Table of Contents
1 Market Overview........................................................................................
3
4.2.4 RHB 104 (GI/Inflammation) ...................................................................................... 2...
4
6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021..
.................................
5
6.4.3 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 &
2022 ...........................
6
8.1 AstraZeneca............................................................................................................
7
8.5.2.1 Focus on product development and regulatory approvals..................................... 56
8.5.3 Recent Devel...
8
List of Tables
Table 1. Definitions........................................................................................
9
Table 23. Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y-
o-Y Growth (%)..........
10
List of Figures
Figure 1. Research Methodology............................................................................
11
1 Market Overview
1.1 Definitions
Table 1. Definitions
Segment Drugs
Antacid & Anti-Ulcerant
Losec/Prilosec, Nexium, Pr...
12
provided for the period 2014 to 2022, considering 2014 and 2015 as the base year.
The report also provides the compound...
13
Figure 3. Gastrointestinal Diseases Market, By Geography
Source: Scalar Market Research Analysis
SAM
PLE
14
2 Executive Summary
The global gastrointestinal diseases market was estimated to be US$XX million in
2016. This market ...
15
2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category (2016 vs. 2022)
Figure 4. Global Gas...
17
3 Market Dynamics
3.1 Drivers
Table 3. Global Gastrointestinal Diseases Market Drivers
Drivers 2014-16 2017- 19 2020-22...
18
3.4 Premium Industry Trends
 Companies focusing on Irritable Bowel Diseases with Diarrhoea therapeutics
will serve as ...
26
5 Global Gastrointestinal Diseases Market, by Drug Category
5.1 Overview
The global gastrointestinal diseases market is...
27
5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category,
2016 & 2022
Figure 6. Global Gastrointestina...
28
Antacid &
Anti-Ulcerant
GIT Anti-
inflammatory
Antiemetic
Anti-
diarrhoea
642.2
Other GIT
Therapeutics
Total
Source: Sc...
29
5.2 Antacid & Anti-Ulcerant
5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region
(2014 – 2022)
Tab...
32
6 Global Gastrointestinal Diseases Market, by Geography
6.1 Overview
The global gastrointestinal diseases market, by ge...
33
6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By
Geography (2014 – 2022)
Table 15. Global Gastroint...
34
6.2 North America
North America recorded US$ XX million revenue, around 50.64% share of the global
gastrointestinal dis...
46
7 Competitive Landscape
7.1 Market Share Analysis
Figure 18. Market Share Analysis of Key Players
Source: Annual Report...
48
8 Company Profiles
8.1 AstraZeneca
8.1.1 Overview
Table 34. AstraZeneca – Company Overview
AstraZeneca - Company Detail...
49
8.1.3 Recent Developments
 Pfizer acquired the exclusive global rights to market AstraZeneca’s Nexium
for OTC indicati...
62
10 Appendix
10.1 Acronyms
Table 42. List of Acronyms
Acronym Expansion
IBS-D Irritable Bowel Syndrome with Diarrhea
H. ...
Upcoming SlideShare
Loading in …5
×

Gastrointestinal diseases market

45 views

Published on

Gastrointestinal Diseases Market is expected to grow from USD 17.27 billion in 2016 and reach USD 19.79 billion in 2022, growing at a CAGR of 2.3% during the forecast period.
Download Free Sample : https://www.scalarmarketresearch.com/request-sample.php?id=12

Published in: Business
  • Be the first to comment

  • Be the first to like this

Gastrointestinal diseases market

  1. 1. 1 Gastrointestinal Diseases Market, by Drug Category, and Geography – Global Opportunity Analysis and Industry Forecast, 2014 – 2022 October 2016
  2. 2. 2 Table of Contents 1 Market Overview..................................................................................................................... 11 1.1 Definitions ....................................................................................................................... 11 1.2 Research Methodology .................................................................................................... 11 1.3 Market Segmentation ...................................................................................................... 12 2 Executive Summary ................................................................................................................. 14 2.1 Market Summary: Global Gastrointestinal Diseases Market ............................................. 14 2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022) ................................................................................................................................. 15 2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2021) ................................................................................................................................. 15 3 Market Dynamics..................................................................................................................... 17 3.1 Drivers ............................................................................................................................. 17 3.2 Restraints......................................................................................................................... 17 3.3 Opportunities................................................................................................................... 17 3.4 Premium Industry Trends................................................................................................. 18 4 Industry Analysis...................................................................................................................... 19 4.1 Major Selling Drug Analysis .............................................................................................. 19 4.1.1 Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis (2015) ................................................................................................................................. 19 4.1.2 Nexium..................................................................................................................... 19 4.1.3 Losec/Prilosec .......................................................................................................... 20 4.1.4 Dexilant.................................................................................................................... 20 4.1.5 Lialda........................................................................................................................ 20 4.1.6 Entyvio ..................................................................................................................... 20 4.1.7 Emend...................................................................................................................... 21 4.1.8 Creon ....................................................................................................................... 21 4.2 Pipeline Analysis .............................................................................................................. 22 4.2.1 Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014 – 2022) .......................................................................................................................... 22 4.2.2 BEKINDA (RHB-104).................................................................................................. 23 4.2.3 RHB-105 (H. pylori)................................................................................................... 23 SAM PLE
  3. 3. 3 4.2.4 RHB 104 (GI/Inflammation) ...................................................................................... 23 4.2.5 Relamorelin.............................................................................................................. 23 4.2.6 Viberzi...................................................................................................................... 24 4.2.7 mAbs Stelara (ustekinumab)..................................................................................... 24 4.2.8 AMG-714.................................................................................................................. 24 4.3 Key event analysis............................................................................................................ 25 5 Global Gastrointestinal Diseases Market, by Drug Category ..................................................... 26 5.1 Overview.......................................................................................................................... 26 5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022. 27 5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) ................................................................................. 27 5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) ................................................................................................................................. 27 5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022 ................................................................................................................................. 28 5.2 Antacid & Anti-Ulcerant ................................................................................................... 29 5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) . 29 5.3 GIT Anti-inflammatory...................................................................................................... 29 5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022).... 29 5.4 Antiemetic ....................................................................................................................... 30 5.4.1 Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ..................... 30 5.5 Anti-diarrhoea.................................................................................................................. 30 5.5.1 Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022)................ 30 5.6 Other GIT Therapeutics .................................................................................................... 31 5.6.1 Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) .. 31 6 Global Gastrointestinal Diseases Market, by Geography .......................................................... 32 6.1 Overview.......................................................................................................................... 32 6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021...... 32 6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022) ................................................................................................................................. 33 6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 ................................................................................................................................. 33 6.2 North America.................................................................................................................. 34 SAM PLE
  4. 4. 4 6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021.. ................................................................................................................................. 34 6.2.2 North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) ................................................................................................................................. 35 6.2.3 North America Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 ................................................................................................................................. 35 6.2.3.1 U.S........................................................................................................................ 35 6.2.3.1.1 Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 35 6.2.3.2 Canada ................................................................................................................. 36 6.2.3.2.1 Gastrointestinal Diseases Market in Canada, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 36 6.2.4 North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .......................................................................................................................... 36 6.3 Europe ............................................................................................................................. 37 6.3.1 Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37 6.3.2 Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022). ................................................................................................................................. 37 6.3.3 Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 . ................................................................................................................................. 38 6.3.3.1 Germany............................................................................................................... 38 6.3.3.1.1 Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y- o-Y Growth (%)................................................................................................................. 38 6.3.3.2 France .................................................................................................................. 39 6.3.3.2.1 Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 39 6.3.3.3 Rest of the Europe................................................................................................ 39 6.3.3.3.1 Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 39 6.3.4 Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) ................................................................................................................................. 39 6.4 Asia-Pacific....................................................................................................................... 40 6.4.1 Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022... 40 6.4.2 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) ................................................................................................................................. 41 SAM PLE
  5. 5. 5 6.4.3 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022 ................................................................................................................................. 41 6.4.3.1 India..................................................................................................................... 41 6.4.3.1.1 Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 41 6.4.3.2 China.................................................................................................................... 42 6.4.3.2.1 Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................................... 42 6.4.3.3 Rest of the Asia-Pacific.......................................................................................... 42 6.4.3.3.1 Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 42 6.4.4 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .......................................................................................................................... 42 6.5 Rest of the World............................................................................................................. 43 6.5.1 Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 ................................................................................................................................. 43 6.5.2 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) .......................................................................................................................... 44 6.5.3 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021............................................................................................................................ 44 6.5.3.1 Latin America........................................................................................................ 44 6.5.3.1.1 Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y Growth (%)....................................................................................................... 44 6.5.3.2 Middle East and Africa.......................................................................................... 45 6.5.3.2.1 Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million) and Y-o-Y Growth (%) .......................................................................................... 45 6.5.4 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022)............................................................................................................ 45 7 Competitive Landscape............................................................................................................ 46 7.1 Market Share Analysis...................................................................................................... 46 7.2 Key Innovators ................................................................................................................. 46 7.2.1 RedHill...................................................................................................................... 46 7.2.2 Allergan.................................................................................................................... 47 7.2.3 Shire......................................................................................................................... 47 8 Company Profiles..................................................................................................................... 48 SAM PLE
  6. 6. 6 8.1 AstraZeneca..................................................................................................................... 48 8.1.1 Overview.................................................................................................................. 48 8.1.2 Key Strategies........................................................................................................... 48 8.1.2.1 Strong research and development activities ......................................................... 48 8.1.2.2 Novel therapeutics in company’s product offering................................................ 48 8.1.3 Recent Developments .............................................................................................. 49 8.2 Valeant (Salix Pharmaceuticals)........................................................................................ 50 8.2.1 Overview.................................................................................................................. 50 8.2.2 Key Strategies........................................................................................................... 50 8.2.2.1 Strategic merger and acquisitions......................................................................... 50 8.2.2.2 US FDA approvals ................................................................................................. 50 8.2.2.3 Strong positioning in gastrointestinal anti-inflammatory therapeutic segment ..... 51 8.2.3 Recent Developments .............................................................................................. 51 8.3 Takeda Pharmaceutical Company Limited ........................................................................ 52 8.3.1 Overview.................................................................................................................. 52 8.3.2 Key Strategies........................................................................................................... 52 8.3.2.1 Conducting awareness programs.......................................................................... 52 8.3.2.2 US FDA approval................................................................................................... 52 8.3.2.3 Expansion of product portfolio through acquisitions............................................. 53 8.3.2.4 Focus on core geography markets......................................................................... 53 8.3.3 Recent Developments .............................................................................................. 53 8.4 Shire ................................................................................................................................ 54 8.4.1 Overview.................................................................................................................. 54 8.4.2 Key Strategy ............................................................................................................. 54 8.4.2.1 Expansion through strategic acquisition................................................................ 54 8.4.2.2 Focus on the development of therapeutics for rare diseases................................. 54 8.4.2.3 Expansion of product portfolio through innovation............................................... 54 8.4.3 Recent Developments .............................................................................................. 55 8.5 Johnson & Johnson Private Limited .................................................................................. 56 8.5.1 Overview.................................................................................................................. 56 8.5.2 Key Strategy ............................................................................................................. 56 SAM PLE
  7. 7. 7 8.5.2.1 Focus on product development and regulatory approvals..................................... 56 8.5.3 Recent Developments .............................................................................................. 56 8.6 Eisai Co., Ltd..................................................................................................................... 58 8.6.1 Overview.................................................................................................................. 58 8.6.2 Key Strategy ............................................................................................................. 58 8.6.2.1 Pricing strategy to emphasize affordability ........................................................... 58 8.6.2.2 Focus on emerging market.................................................................................... 58 8.6.2.3 Transformation of product portfolio ..................................................................... 58 8.6.3 Recent Developments .............................................................................................. 59 8.7 Allergan ........................................................................................................................... 60 8.7.1 Overview.................................................................................................................. 60 8.7.2 Key Strategies........................................................................................................... 60 8.7.2.1 Strategic merger and acquisitions......................................................................... 60 8.7.3 Recent Developments .............................................................................................. 60 9 Scalar 360 Degree Market Perspective..................................................................................... 61 9.1 Global Gastrointestinal Diseases Market Trend ................................................................ 61 10 Appendix ................................................................................................................................. 62 10.1 Acronyms......................................................................................................................... 62 SAM PLE
  8. 8. 8 List of Tables Table 1. Definitions.................................................................................................................... 11 Table 2. Market Summary: Global Gastrointestinal Diseases Market.......................................... 14 Table 3. Global Gastrointestinal Diseases Market Drivers........................................................... 17 Table 4. Global Gastrointestinal Diseases Market Restraints...................................................... 17 Table 5. Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis (2015) .................................................................................................................................... 19 Table 6. Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014 – 2022) .................................................................................................................................... 22 Table 7. Key event analysis- Global Gastrointestinal Diseases Market........................................ 25 Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) ...................................................................................................... 27 Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................... 27 Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) ..... 29 Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022)........ 29 Table 12. Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ......................... 30 Table 13. Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022).................... 30 Table 14. Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) ...... 31 Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022). .................................................................................................................................... 33 Table 16. North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) .................................................................................................................................... 35 Table 17. Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 36 Table 18. Gastrointestinal Diseases Market in Rest of Canada, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 36 Table 19. North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................. 36 Table 20. Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) 38 Table 21. Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 38 Table 22. Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 39 SAM PLE
  9. 9. 9 Table 23. Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y- o-Y Growth (%)................................................................................................................................ 39 Table 24. Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................... 39 Table 25. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) .................................................................................................................................... 41 Table 26. Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth (%) .................................................................................................................................... 42 Table 27. Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth (%) 42 Table 28. Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million) and Y-o-Y Growth (%) ...................................................................................................................... 42 Table 29. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) 42 Table 30. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) 44 Table 31. Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y Growth (%) 45 Table 32. Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million) and Y-o-Y Growth (%) ...................................................................................................................... 45 Table 33. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) .................................................................................................................................. 45 Table 34. AstraZeneca – Company Overview ............................................................................... 48 Table 35. Valeant – Company Overview....................................................................................... 50 Table 36. Takeda Pharmaceutical Company Limited – Company Overview................................... 52 Table 37. Shire – Company Overview........................................................................................... 54 Table 38. Johnson & Johnson Private Limited – Company Overview ............................................ 56 Table 39. Eisai Co., Ltd. – Company Overview.............................................................................. 58 Table 40. Allergan– Company Overview....................................................................................... 60 Table 41. Global Gastrointestinal Diseases Market Trend ............................................................ 61 Table 42. List of Acronyms........................................................................................................... 62 SAM PLE
  10. 10. 10 List of Figures Figure 1. Research Methodology................................................................................................. 12 Figure 2. Gastrointestinal Diseases Market, By Drug Category..................................................... 12 Figure 3. Gastrointestinal Diseases Market, By Geography.......................................................... 13 Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022) 15 Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2021) 15 Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 .... 27 Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022 28 Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021.......... 32 Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 33 Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 34 Figure 11. North America Gastrointestinal Diseases Market Size (US$ illion), By Country, 2016 & 2021 35 Figure 12. Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37 Figure 13. Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022 38 Figure 14. Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022... 40 Figure 15. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022 41 Figure 16. Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 43 Figure 17. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 44 Figure 18. Market Share Analysis of Key Players........................................................................ 46 SAM PLE
  11. 11. 11 1 Market Overview 1.1 Definitions Table 1. Definitions Segment Drugs Antacid & Anti-Ulcerant Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron, Pentozol, Pariet/Aciphex, Carafate/Sulcrate, Cytotec, and Selbex GIT Anti-inflammatory Lialda, Delzicol, Asacol, Pentasa, Uceris, Apriso, Entyvio, Simponi /Simponi Aria, and Remicade Antiemetic Agent Emend, Aloxi, Kytril and others Anti-diarrhoea Agent Enterogermina, Smecta, Imodium, Bioflor, Seirogan A and others Other GIT Therapeutics Creon, Donnatal, Daikenchuto, Bifico, Linzess (US)/Constella, and others Pipeline Drugs BEKINDA (RHB-102), RHB-105 (H. pylori), RHB 104, Relamorelin, Viberzi, mAbs Stelara (ustekinumab) and AMG-714 Source: Scalar Market Research Analysis 1.2 Research Methodology The research methodology for market research reports at Scalar Market Research includes a combination of top-down and bottom-up research formats. Continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensure high quality data that can be leveraged for actionable insights. The global market for gastrointestinal diseases involves the study of different branded and generic gastrointestinal therapeutics. The 'Global Gastrointestinal Diseases Market – Industry Analysis, Market Size and Forecast (2014–2022)' report includes market size and forecast, estimated from the period 2016 to 2022. This report encompasses a detailed study for various gastrointestinal therapeutic used for the treatment of conditions such as ulcerative colitis, irritable bowel diseases, celiac diseases, and many others. Drug category segment is primarily categorized into Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic Agent, Anti-diarrhoea Agent and Other GIT Therapeutics. The market size and forecast for each drug category type has been SAM PLE
  12. 12. 12 provided for the period 2014 to 2022, considering 2014 and 2015 as the base year. The report also provides the compounded annual growth rate and due to (% CAGR) for the forecast period 2016 to 2022 for each drug category. Based on Geography, the market is segmented as North America, Europe, Asia- Pacific and Rest of the World (RoW). The market size and forecast for geography has been estimated for the period 2014 to 2022 in terms of revenue (US$ million). The report also estimates the compounded annual growth rate (CAGR %) during the forecast period from 2016 to 2022 for all the geographies mentioned above. Figure 1. Research Methodology Source: Scalar Market Research Analysis 1.3 Market Segmentation Figure 2. Gastrointestinal Diseases Market, By Drug Category Source: Scalar Market Research Analysis Global Market Size Market-specific Revenuesof Key Market Players Revenuesof Key Market Players GlobalMarket Size Segment-specific MarketSize Regional Market Size Bottom-up Top-down SAM PLE
  13. 13. 13 Figure 3. Gastrointestinal Diseases Market, By Geography Source: Scalar Market Research Analysis SAM PLE
  14. 14. 14 2 Executive Summary The global gastrointestinal diseases market was estimated to be US$XX million in 2016. This market is expected to grow at a CAGR of XX% in the forecast period and is expected to be US$XX billion in 2022. This report segments the global gastrointestinal diseases market by drug category and geography. 2.1 Market Summary: Global Gastrointestinal Diseases Market Table 2. Market Summary: Global Gastrointestinal Diseases Market Factors 2016 2022 Global Gastrointestinal Diseases Market (US$ million) 17,271.2 14,859.7 Largest Revenue Generating Market, by Drug Category (US$ million) Lowest Revenue Generating Market, by Drug Category (US$ million) Segment with Highest Growth Rate, by Drug Category Largest Revenue Generating Market, by Geography (US$ million) Lowest Revenue Generating Market, by Geography (US$ million) Segment with Highest Growth Rate, by Geography Key Market Players (2015) Pipeline Drugs Source: Scalar Market Research analysis SAM PLE
  15. 15. 15 2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022) Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022) Source: Scalar Market Research analysis Of the different drug category, antacid & anti-ulcerant accounted for the largest share of the global market revenue. Growth of this segment is majorly attributed to the approval of novel proton pump inhibitors by government regulatory. In addition, growing demand for gastrointestinal therapeutics such as Nexium, Dexilant, and Sulcrate in developing as developed countries drives the market growth of this segment. However, anti-diarrohea segment recorded around 3.5% share of the global market and is expected lose its market share during the forecast period owing to the generic drug entry. 2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2022) Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2022) 45.2% 26.7% 12.5% 3.6% 12.0% 2016 40.7% 38.6% 8.2% 2.4% 10.1% 2022 Antacid & Anti- Ulcerant GIT Anti- inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics SAM PLE
  16. 16. 17 3 Market Dynamics 3.1 Drivers Table 3. Global Gastrointestinal Diseases Market Drivers Drivers 2014-16 2017- 19 2020-22 ● ● ● ◕ ◕ ● ◑ ● ● Source: Scalar Market Research Analysis Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact 3.2 Restraints Table 4. Global Gastrointestinal Diseases Market Restraints Restraints 2014-16 2017- 19 2020-22 ◑ ● ◕ ◕ ◑ ◑ Source: Scalar Market Research Analysis Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact 3.3 Opportunities  Development of biologic therapeutics for the treatment of gastrointestinal diseases due to its favorable safety profile  Development of monoclonal antibody related gastrointestinal therapeutics  Increasing investment in emerging market of Asia-Pacific SAM PLE
  17. 17. 18 3.4 Premium Industry Trends  Companies focusing on Irritable Bowel Diseases with Diarrhoea therapeutics will serve as potential market to record high growth profit SAM PLE
  18. 18. 26 5 Global Gastrointestinal Diseases Market, by Drug Category 5.1 Overview The global gastrointestinal diseases market is categorized into different types of drug category such as Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Anti- diarrhoea, and other GIT Therapeutics. This chapter analyzes the market revenue generated by the different branded and generic therapeutics falls under different drug categories. Antacid and Anti-Ulcerant section covers the study of variety of Omeprazole drugs such as Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron, Pentozol, Pariet/Aciphex, and drugs such as Sucralfate (Carafate/Sulcrate) , Cytotec and others. Companies such as AstraZeneca, Takeda Pharmaceuticals and Daichi Sankyo are aggressively investing in research and development activities to develop new anti-ulcerant moieties which help this segment to grow during the forecast period. However, negative growth of the segment is majorly attributed to the patent expiry of AstraZeneca’s two brand drug, Losec/Prilosec and Nexium. On other side, the demand for Takeda Pharmaceutical’s proton pump inhibitor (Dexilant) is increasing due to its unique mechanism of action which is considered as positive impact for the growth of this segment. GIT Anti-inflammatory comprises drugs such as Lialda, Delzicol, Asacol, Pentasa, Uceris, Apriso, Entyvio, Remicade, and others. This segment is anticipated to growth with the positive growth rate of XX% during the forecast year 2016 to 2022. The growth of the segment is majorly supported by the launch of Takeda’s vedolizumab category of drug (Entyvio). This monoclonal antibody based Anti-inflammatory drug is expected to hit the market with highest growth rate due to its high efficacy for the treatment of gastrointestinal diseases. Additionally, drug molecules such as Lialda (Shire, Inc.) and Apriso (Salix Pharmaceutical) is also projected to support the growth of this market segment owing to the patent exclusivity. Antiemetic drug agents include the market estimation covering brand or generic drugs such as Emend, Aloxi, Kytril and many others. Study for the gastrointestinal drugs such as Enterogermina, Smecta, Imodium, and others are covered under the anti-diarrhoea drug segment. While, Other GIT Therapeutics includes the revenue generation of therapeutics such as Donnatal, Creon, Daikenchuto, Linzess/Constella, and many others. SAM PLE
  19. 19. 27 5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 Source: Scalar Market Research Analysis 5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022) Drug 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAGR% (2016 – 2022) Global Commercialize Drug Revenue Global Pipeline Drug Revenue 74.5% Total Source: Scalar Market Research Analysis 5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022) Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category(2014 – 2022) Drug Category 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAGR% (2016 – 2022) 45.2% 26.7% 12.5% 3.6% 12.0% 2016 40.7% 38.6% 8.2% 2.4% 10.1% 2022 Antacid & Anti- Ulcerant GIT Anti- inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics SAM PLE
  20. 20. 28 Antacid & Anti-Ulcerant GIT Anti- inflammatory Antiemetic Anti- diarrhoea 642.2 Other GIT Therapeutics Total Source: Scalar Market Research Analysis 5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022 Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022 Source: Scalar Market Research Analysis 7,798.4 4,619.0 2,152.0 621.2 2,080.6 6,045.6 5,729.9 1,215.8 363.0 1,505.5 Antacid& Anti- Ulcerant GIT Anti-inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics US$million 2016 2022 SAM PLE
  21. 21. 29 5.2 Antacid & Anti-Ulcerant 5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAGR% (2016 – 2022) North America Europe Asia-Pacific Rest of the World 442.8 Total Source: Scalar Market Research Analysis 5.3 GIT Anti-inflammatory 5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAGR% (2016 – 2022) North America Europe Asia-Pacific Rest of the World Total 3.7% Source: Scalar Market Research Analysis SAM PLE
  22. 22. 32 6 Global Gastrointestinal Diseases Market, by Geography 6.1 Overview The global gastrointestinal diseases market, by geography is categorized into North America, Europe, Asia-Pacific, and Rest of the World. This chapter analyzed the revenue generation by each region in terms of US$ million. The global market for gastrointestinal diseases is majorly dominated by the developed regions of North America and Europe which captured almost XX% share of the global market revenue in 2016. Growth of this region is majorly attributed to the rising approval of novel gastrointestinal therapeutics coupled with growing incidence of various gastrointestinal diseases. Among which, North America is accounted for XX% share of the total revenue in 2016. Approval of GIT Anti-inflammatory such as Lialda and Entyvio helped the region to grow with steady growth rate during the forecast period. However, increasing incidence of gastrointestinal diseases such as irritable bowel syndrome and ulcerative colitis in Asia-Pacific and Rest of the World region drives the growth of the market during the future period. 6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022 Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022 Source: Scalar Market Research Analysis 50.6% 35.9% 9.5% 4.0% 2016 50.5% 36.4% 9.4% 3.6% 2022 North America Europe Asia Rest of the World SAM PLE
  23. 23. 33 6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022) Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By Geography(2014 – 2022) Geography 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAGR% (2016 – 2022) North America Europe Asia-Pacific Rest of the World 761.1 Total Source: Scalar Market Research Analysis 6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022 Source: Scalar Market Research Analysis 8,745.8 6,205.5 1,635.2 684.8 7,511.1 5,411.3 1,401.6 535.7 NorthAmerica Europe Asia Rest of the World US$million 2016 2022 SAM PLE
  24. 24. 34 6.2 North America North America recorded US$ XX million revenue, around 50.64% share of the global gastrointestinal diseases market. Gastrointestinal diseases market in North America is majorly supported by the favorable government initiatives to introduce novel GIT therapeutics. For example, in May 2014, U.S. FDA approved Takeda Pharmaceuticals’ GIT Anti-inflammatory therapeutic, Entyvio. The drug is indicated for the treatment of severe ulcerative colitis and moderate to severe Crohn‘s disease. Takeda Pharmaceutical is projecting high sales growth of this integrin receptor antagonist in the U.S. market owing to its proven safety and efficacy in clinical trials for the treatment of ulcerative colitis and Crohn‘s disease. Additionally, in November 2013, the U.S. Centers for Disease Control and Prevention estimated that more than 21 million people in the U.S. get infected with noro-virus and develop acute gastroenteritis each year which further stimulated the demand for GIT therapeutics. However, patent expiry of blockbuster gastrointestinal therapeutics such as Nexium, Pariet/Aciphex and many others adversely affected the growth of the market. 6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 Source: Scalar Market Research Analysis 87.1% 12.9% 2016 84.1% 15.9% 2022 U.S. Canada SAM PLE
  25. 25. 46 7 Competitive Landscape 7.1 Market Share Analysis Figure 18. Market Share Analysis of Key Players Source: Annual Reports, Press Releases & Scalar Market Research analysis 7.2 Key Innovators 7.2.1 RedHill RedHill is an emerging biopharmaceutical company, primarily focused on commercialize and development of molecules for the treatment of gastrointestinal and inflammatory diseases. This company is considered as one of the growing company owing to the impressive late-stage clinical pipeline drugs for gastrointestinal diseases. The company investigates gastrointestinal therapeutics namely Bekinda, RHB-105 and RHB-104 under the phase - 3 clinical study which is expected to hit the market in between 2018 - 2019. Among which, Bekinda contains Ondansetron drug, filed for the antiemetic indication. The drug is primarily used to prevent radiation-induced nausea and vomiting. Additionally, the company has initiated a Phase - 2 clinical study with Bekinda for the treatment of Irritable bowel syndrome with diarrhoea. Furthermore, the company is also investigating therapeutics for the treatment of H. pylori infection (RHB-105) and Crohn’s disease (RHB-104). Thus, it looks that the company have very interesting market potential to 8.3% 15.0% 12.6% 3.6% 5.0% 55.4% Market Share (Value %), 2015 Allergan AstraZeneca Takeda Pharmaceutical Company Limited Daichi Sankyo Eisai Co., Ltd. Other SAM PLE
  26. 26. 48 8 Company Profiles 8.1 AstraZeneca 8.1.1 Overview Table 34. AstraZeneca – Company Overview AstraZeneca - Company Detail Headquarters London, UK Year of Establishment 1999 No. of Employees (2015) More than 50,000 Gastrointestinal Therapeutics Losec/Prilosec and Nexium Revenue (2015) US$ 23,641 million Source: Annual Reports, Investor Presentations,Primary Interviews andScalar Market Research Analysis 8.1.2 Key Strategies 8.1.2.1 Strong research and development activities AstraZeneca is one of the key leaders for the global gastrointestinal drugs market. The company is aggressively focusing on developing novel gastrointestinal therapeutics for the treatment of conditions such as ulcerative colitis, irritable bowel syndrome and Crohn’s diseases. In 2015, the company spent US$ 5,997 million for research and development activities, up 7% as compared to the previous year. The company aimed to develop new medicines notably in the segment of diabetes and gastrointestinal diseases. 8.1.2.2 Novel therapeutics in company’s product offering Owing to the strong research and development focus on gastrointestinal disease segment, the company has developed novel therapeutics which has shown high efficacy and safety for the treatment of GIT disorders. For example, the company offers three gastrointestinal drugs such as Entocort (budesonide), Losec/Prilosec (omeprazole) and Nexium (esomeprazole magnesium). These drugs are used for the treatment and cure of GIT problems such as inflammatory bowel disease and acid related disorders. SAM PLE
  27. 27. 49 8.1.3 Recent Developments  Pfizer acquired the exclusive global rights to market AstraZeneca’s Nexium for OTC indications worldwide in 2012, and launched OTC Nexium 20mg in the US and Europe in 2014.  In November 2015, the company entered into an agreement with Perrigo Company plc for the divestment of US rights to Entocort, a gastroenterology medicine for patients with mild to moderate Crohn’s disease. Under this agreement, Perrigo acquired the right to sell Entocort capsules SAM PLE
  28. 28. 62 10 Appendix 10.1 Acronyms Table 42. List of Acronyms Acronym Expansion IBS-D Irritable Bowel Syndrome with Diarrhea H. pylori Helicobacter Pylori GIT Disease Gastrointestinal Disease U.S. FDA U.S. Food and Drug Administration DDW Digestive Disease Week Source: Scalar Market Research Analysis SAM PLE

×